Provisional Agenda
(subject to change)
All times mentioned refer to British Standard Time (BST).
World Time Converter: https://www.worldtimebuddy.com
Presentation language: English
We have tried to group similar talks, but due to the wide geographical locations of our speakers, this may not always have been possible.
Day 1: Tuesday 20th April 2021
1220: Welcome and introduction
Session 1: Chair – Dr Sylvain Ladame
1230: Professor Tom Brown, Professor of Chemistry, and Dr Ysobel Baker, Postdoctoral Researcher, Chemistry Research Labs, University of Oxford, and ATDBio Ltd, Oxford, UK (Website)
Recent synthetic, biophysical and biological studies on artificial nucleic acid backbones
1300: Dr Marcel Hollenstein, Head of Structure – Bioorganic Chemistry of Nucleic Acids, Department of Structural Biology and Chemistry, Pasteur Institute, Paris, France (Website)
Chemical methods to isolate modified aptamers
1330: Professor Achim Aigner, Professor, Rudolf-Boehm-Institut für Pharmakologie und Toxikologie, Selbst Abteilung Klinische Pharmakologie, Leipzig, Germany
Chemically improved, PEI-based polymer systems for RNA therapeutics: siRNA/miRNA delivery and beyond
1400: Professor Elena Bichenkova, Reader, Division of Pharmacy & Optometry, University of Manchester, Manchester, UK (Website)
Towards multiple catalytic turnover: “smart”, responsive peptidyl- oligonucleotide conjugates for selective knockdown of pathogenic RNA
1430: Dr Kim Lennox, Staff Scientist, Integrated DNA Technologies, Coralville, Iowa, USA
Methodology considerations for circular RNA knockdown
1500: Break
Session 2: Chair – Professor Tom Brown
1520: Dr Nebojsa Janjic, Chief Science Officer, SomaLogic, Inc, Boulder, CO, USA (Website), and Professor William James, Professor, Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, UK (Website)
Modified DNA aptamers to SARS-CoV-2 spike protein for diagnostic and therapeutic uses
1550: Professor Dr Günter Mayer, University of Bonn, Life & Medical Sciences Institute (LIMES), Chemical Biology, Bonn, Germany (Website)
A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection by an RBD independent mechanism
1620: Dr David Evans, Chief Scientific Officer, Sirnaomics, Inc, Cambridge, MA, USA (Website)
Novel SiRNA constructs for oncology indications
1650: Dr Sylvain Ladame, Reader in Biosensor Development, Imperial College London, London, UK (Website)
Devices for cancer diagnosis based on microRNA biomarkers from bodily fluids (provisional title)
1720: Professor Larry Gold (Keynote Speaker), Professor of Molecular Cellular & Developmental Biology, SomaLogic Inc, and College of Arts and Sciences, University of Colorado Boulder, Boulder, CO, USA
TBA
1800: Close of Day 1
Day 2: Wednesday 21st April
1220: Welcome and introduction
Session 3 (ECR Symposium): Chair – Dr Maaike van Putten
1230: Dr Ala’a Said Shraim, Assistant Professor, Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Al-Ahliyya Amman University, Amman, Jordan
Developing and characterizing chemically modified RNA aptamers targeting wild type and mutated c-KIT receptor tyrosine kinases
1250: Miss Anna Jonczyk, PhD Student, LIMES Institute, University of Bonn, Bonn, Germany
Identification and characterization of CCL22 and CCL17 recognizing aptamers inhibiting immune cell chemotaxis
1310: Miss Chiara Figazzolo, PhD Student, Université de Paris and Institut Pasteur, Laboratory for Bioorganic Chemistry of Nucleic Acids, Paris, France
Synthesis of a vancomycin-modified uridine to be included in aptamers
1330: Mr Sven Epple, Graduate Student, Chemistry Department, University of Oxford, Oxford, UK
Artificial Backbones in genetic templates
1350: Dr Ngoc Lu-Nguyen, Postdoctoral Research Assistant, Department of Biological Sciences, Royal Holloway University of London, London, UK
Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in a mouse model
1410: Dr Thomas Pataillot-Meakin, Imperial College London, London, UK
Size profiles of circulating cell-free nucleic acids as a biomarker to predict and monitor treatment responses in cancer
1430: Break
Session 4: Chair – Dr Nebojsa Janjic
1450: Professor Annemieke Aartsma-Rus (Keynote Speaker), Professor of Human Genetics, Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands (Website)
Optimizing antisense mediated exon skipping for Duchenne muscular dystrophy and ultrarare diseases
1530: Dr Maaike van Putten, Postdoctoral Researcher (symposium moderator), Leiden University Medical Center, DMD genetic therapy group, Leiden, the Netherlands (Website)
The potential of the antisense oligonucleotide-mediated exon-skipping therapy to treat the brain in Duchenne muscular dystrophy
1600: Professor Arwyn Tomos Jones, Professor of Membrane Traffic & Drug Delivery and Director of Research Innovation & Engagement, Cardiff University, Cardiff, UK (Website)
Endocytic Profiling as a technology patform for characterising LNP delivery of mRNA into cancer cell models
1630: Professor Bruce Sullenger, Dorothy W Beard Distinguished Professor of Experimental Surgery, Duke University, Durham, North Carolina, USA (Website)
Antithrombotic aptamers in the era of COVID-19
1700: Discussion and close
